These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20306021)

  • 1. Denosumab-related osteonecrosis of the jaws.
    Kyrgidis A; Toulis KA
    Osteoporos Int; 2011 Jan; 22(1):369-70. PubMed ID: 20306021
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
    Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
    J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteonecrosis of the jaw.
    Drozdzowska B
    Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More about osteonecrosis.
    Finkelman RD; Clemons M; Bouganim N
    J Am Dent Assoc; 2011 Apr; 142(4):371-2; author reply 372-4. PubMed ID: 21454842
    [No Abstract]   [Full Text] [Related]  

  • 5. A new class of drugs to prevent osteoporosis may be associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(1):10-2. PubMed ID: 21613033
    [No Abstract]   [Full Text] [Related]  

  • 6. Root canal therapy for the prevention of osteonecrosis of the jaws: an evidence-based clinical update.
    Kyrgidis A; Arora A; Lyroudia K; Antoniades K
    Aust Endod J; 2010 Dec; 36(3):130-3. PubMed ID: 21140589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw in a patient on Denosumab.
    Aghaloo TL; Felsenfeld AL; Tetradis S
    J Oral Maxillofac Surg; 2010 May; 68(5):959-63. PubMed ID: 20149510
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteonecrosis of jaw with the use of denosumab.
    Akhtar NH; Afzal MZ; Ahmed AA
    J Cancer Res Ther; 2011; 7(4):499-500. PubMed ID: 22269422
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of denosumab in giant-cell tumour of bone.
    Thomas D; Carriere P; Jacobs I
    Lancet Oncol; 2010 Sep; 11(9):815. PubMed ID: 20816372
    [No Abstract]   [Full Text] [Related]  

  • 10. Denosumab for bone metastases from breast cancer: a new therapy option?
    Aapro MS
    J Clin Oncol; 2011 May; 29(14):e419-20; author reply e421-4. PubMed ID: 21464408
    [No Abstract]   [Full Text] [Related]  

  • 11. [Possible denosumab-induced jaw osteonecrosis in the treatment of osteoporosis. A case report].
    Selvi Sabater P; Rizo Cerdá AM; Titos Arcos JC; Espuny Miró A
    Farm Hosp; 2014 May; 38(3):248-9. PubMed ID: 24951910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw and the role of macrophages.
    Pazianas M
    J Natl Cancer Inst; 2011 Feb; 103(3):232-40. PubMed ID: 21189409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of denosumab in giant-cell tumour of bone.
    Kyrgidis A; Toulis K
    Lancet Oncol; 2010 Jun; 11(6):513-4. PubMed ID: 20522379
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
    O'Halloran M; Boyd NM; Smith A
    Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New oncology drugs and osteonecrosis of the jaw (ONJ).
    Migliorati CA; Covington JS
    J Tenn Dent Assoc; 2009; 89(4):36-8; quiz 38-9. PubMed ID: 20102031
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of current literature and implications of RANKL inhibitors for oral health care providers.
    Epstein MS; Ephros HD; Epstein JB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
    Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
    J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
    Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
    J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
    Neuprez A; Rompen E; Crielaard JM; Reginster JY
    Calcif Tissue Int; 2014 Jul; 95(1):94-6. PubMed ID: 24804929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.